mega genomics
Genetic testing platform for consumers and cancer screening.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $20.0m | IPO |
| Total Funding | 000k | ||
| CNY | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 64 % | 17 % | (39 %) | 4 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 63 % | 61 % | 51 % | 12 % | 23 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 24 % | 39 % | 33 % | (12 %) | 20 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 4 % | 2 % | 5 % | - | - |
Source: Company filings or news article
Mega Genomics Limited is a genetic testing platform company in China, founded in 2016, with a focus on consumer genetic testing and cancer screening services. The company's controlling shareholder is Yu Rong, who is also the chairman and controller of Meinian Health, a strategic partner. Mega Genomics went public on the Hong Kong Stock Exchange on June 22, 2022.
The company operates through two primary business segments: consumer genetic testing and cancer screening services. The consumer division provides a wide array of tests, including risk assessments for various cancers, chronic diseases, and neurodegenerative conditions like Alzheimer's and Parkinson's. It also offers services related to nutrition, metabolism, and pharmacogenetics. The cancer screening segment provides kits for detecting colorectal, gastric, and cervical cancers, among others. The company serves clients through collaborations with healthcare institutions, such as health checkup centers and hospitals, and has also established partnerships with e-commerce and online healthcare platforms. Its business model integrates the entire industry chain, from internal research and development to its sales and marketing network. Revenue is generated from the sale of these testing services and kits, with a significant portion historically derived from its strategic relationship with Meinian Health.
Since its inception, Mega Genomics has performed over 19 million genetic tests and has the capacity to process up to 50,000 samples daily. By the end of 2023, the company had partnered with over 1,800 healthcare institutions in more than 340 cities across China. According to Frost & Sullivan, based on the cumulative number of tests, Mega Genomics was the largest consumer genetic testing platform in China as of December 31, 2021.
Keywords: genetic testing, cancer screening, consumer genetics, preventive healthcare, DNA testing, risk assessment, China healthcare, genomics platform, molecular diagnostics, disease screening, whole-exome sequencing, pharmacogenetics, hereditary cancer testing, colorectal cancer screening, health management, precision medicine, IVD products, Meinian Health, public company, diagnostics